A novel recombinant peptide containing only two T-cell tolerance epitopes of chicken type II collagen that suppresses collagen-induced arthritis

Molecular Immunology

Volumn 46, Issue 4, 2009, Pages 729-737

  Xi, Caixia ^a   Tan, Liuxin ^a   Sun, Yeping ^a   Liang, Fei ^a   Liu, Nan ^a   Xue, Hong ^a   Luo, Yuan ^a   Yuan, Fang ^a   Sun, Yuying ^a   Xi, Yongzhi ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Chicken type II collagen; Collagen induced arthritis; Oral tolerance; Rheumatoid arthritis; T cell tolerogenic epitope

Indexed keywords

ANTIBODY; COLLAGEN; COLLAGEN TYPE 2; CYTOKINE; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN; NITRILOTRIACETIC ACID; PEPTIDE; RECOMBINANT PEPTIDE COLLAGEN TOLERANCE EPITOPE 1-2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFICACY; FEMALE; IN VIVO STUDY; INCIDENCE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROKARYOTIC CELL; RHEUMATOID ARTHRITIS; SPLEEN CELL; SWELLING; T LYMPHOCYTE; TH1 CELL; TH3 CELL;

ANIMALS; ANTIBODIES; ARTHRITIS, EXPERIMENTAL; CHICKENS; COLLAGEN TYPE II; DESENSITIZATION, IMMUNOLOGIC; EPITOPES; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; MICE, INBRED STRAINS; PEPTIDES; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; BOVINAE; MUS; PROKARYOTA;

EID: 58349091708     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.10.016     Document Type: Article

References (50)

1. Ausar S.F., Beltramo D.M., Castagna L.F., Quintana S., Slivera E., Kalayan G., Revigliono M., Landa C.A., and Bianco I.D. Treatment of rheumatoid arthritis by oral administration of bovine tracheal type II collagen. Rheumatol. Int. 20 (2001) 138-144
2. Barnett M.L., Combitchi D., and Trentham D.E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 39 (1996) 623-628
3. Barnett M.L., Kremer J.M., St Clair E.M., Clegg D.O., Furst D., Weisman M., Fletcher M.J., Chasan-Taber S., Finger E., Morales A., Le C.H., and Trentham D.E. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 41 (1998) 290-297
4. Brand D.D., Myers L.K., Terato K., Whittington K.B., Stuart J.M., Kang A.H., and Rosloniec E.F. Characterization of the T cell determinants in the induction of autoimmune arthritis by bovine alpha 1(II)-CB11 in H-2q mice. J. Immunol. 152 (1994) 3088-3097
5. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5 (2006) 564-576
6. Bulleid N.J., John D.C., and Kadler K.E. Recombinant expression systems for the production of collagen. Biochem. Soc. Trans. 28 (2000) 350-353
7. b) mice: new insights into an important disease model of rheumatoid arthritis. Eur. J. Immunol. 30 (2000) 1568-1575
8. +T cell responses: the alternative approaches. Annu. Rev. Immunol. 15 (2004) 297-322
9. Deak F., Argraves W.S., Kiss I., Sparks K.J., and Goetinck P.F. Primary structure of the telopeptide and a portion of the helical domain of chicken type II procollagen as determined by DNA sequence analysis. Biochem. J. 229 (1985) 189-196
10. Dzhambazov B., Nandakumar K.S., Kihlberg J., Fugger L., Holmdahl R., and Vestberg M. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J. Immunol. 176 (2006) 1525-1533
11. Gamble B.M., Gallaqher P.A., Shoemaker J.A., et al. An investigation of the chemical stability of arsenosugars in simulated gastric juice and acidic environments using IC-ICP-MS and IC-ESI-MS/MS. Analyst 127 (2002) 781-785
12. Hueber W., Kidd B.A., Tomooka B.H., Lee B.J., Bruce B., Fries J.F., Sonderstrup G., Monach P., Drijfhout J.W., van Venrooij W.J., Utz P.J., Genovese M.C., and Robinson W.H. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum. 52 (2005) 2645-2655
13. Jin Y., Li J., Zhang Y.F., and Xu S.Y. The preparation of type II collagen2induced arthritis model in mice. Chin. Pharmacol. Bull. 15 (1999) 560-562
14. Kalil A.C. New drugs for rheumatoid arthritis. N. Engl. J. Med. 351 (2004) 2659-2661
15. Kim W.U., Cho M.L., Jung Y.O., Min S.Y., Park S.W., Min D.J., Yoon J.H., and Kim H.Y. Type II collagen autoimmunity in rheumatoid arthritis. Am. J. Med. Sci. 327 (2004) 202-211
16. Mainni R.N., and Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51 (2000) 207-229
17. Malmstrom V., Kjellen P., and Holmdahl R. Type II collagen in cartilage evokes peptide-specific tolerance and skews the immune response. J. Autoimmun. 11 (1998) 213-221
18. McKown K.M., Carbone L.D., Kaplan S.B., Aelion J.A., Lohr K.M., Cremer M.A., Bustillo J., Gonzalez M., Kaeley G., Steere E.L., Somes G.W., Myers L.K., Seyer J.M., Kang A.H., and Postlethwaite A.E. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. 42 (1999) 1204-1208
19. Miller E.J., Woodall D.L., and Vail M.S. Biosynthesis of cartilage collagen. Use of pulse labeling to order the cyanogen bromide peptides in the α1(II) chain. J. Biol. Chem. 248 (1973) 1666-1671
20. Miyahara H., Myers L.K., Rosloniec E.F., Brand D.D., Seyer J.M., Stuart J.M., and Kang A.H. Identification and characterization of a major tolerogenic T-cell epitope of type II collagen that suppresses arthritis in B10. RIII mice. Immunology 86 (1995) 110-115
21. Myers L.K., Rosloniec E.F., Seyer J.M., Stuart J.M., and Kang A.H. A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen-induced arthritis. J. Immunol. 150 (1993) 4652-4658
22. Myers L.K., Seyer J.M., Stuart J.M., Terato K., David C.S., and Kang A.H. T cell epitopes of type II collagen that regulate murine collagen-induced arthritis. J. Immunol. 151 (1993) 500-505
23. Myers L.K., Cooper S.W., Terato K., Seyer J.M., Stuart J.M., and Kang A.H. Identification and characterization of a tolerogenic T cell determinant within residues 181-209 of chick type II collagen. Clin. Immunol. Immunopathol. 75 (1995) 33-38
24. Myers L.K., Miyahara H., Terato K., Seyer J.M., Stuart J.M., and Kang A.H. Collagen-induced arthritis in B10.RIII mice (H-2r): identification of an arthritogenic T-cell determinant. Immunology 84 (1995) 509-513
25. Myers L.K., Brand D.D., Ye X.J., Cremer M.A., Rosloniec E.F., Bodo M., Myllyharju J., Helaakoski T., Nokelainen M., Pihlajaniemi T., Kivirikko K., Yang C.L., Ala-Kokko L., Prockop D.J., Notbohm H., Fietzek P., Stuart J.M., and Kang A.H. Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice. Immunology 95 (1998) 631-639
26. Myers L.K., Sakurai Y., Tang B., He X., Rosloniec E.F., Stuart J.M., and Kang A.H. Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis Rheum. 46 (2002) 3369-3377
27. Myers L.K., Sakurai Y., Rosloniec E.F., Stuart J.M., and Kang A.H. An analog peptide that suppresses collagen-induced arthritis. Am. J. Med. Sci. 327 (2004) 212-216
28. Myers L.K., Tang B., Brand D.D., Rosloniec E.F., Stuart J.M., and Kang A.H. Efficacy of modified recombinant type II collagen in modulating autoimmune arthritis. Arthritis Rheum. 50 (2004) 3004-3011
29. Myers L.K., Myllyharju J., Nokelainen M., Brand D.D., Cremer M.A., Stuart J.M., Bodo M., Kivirikko K.I., and Kang A.H. Relevance of posttranslational modifications for the arthritogenicity of type II collagen. J. Immunol. 172 (2004) 2970-2975
30. Myllyharju J., and Kivirikko K.I. Collagens and collagen-related diseases. Ann. Med. 33 (2001) 7-21
31. Myllyharju J., Nokelainen M., Vuorela A., and Kivirikko K.I. Expression of recombinant human type I-III collagens in the yeast pichia pastoris. Biochem. Soc. Trans. 28 (2000) 353-357
32. Ninomiya Y., Showalter A.M., van der Rest M., Seidah N.G., Chretien M., and Olsen B.R. Structure of the carboxyl propeptide of chicken type II procollagen determined by DNA and protein sequence analysis. Biochemistry 23 (1984) 617-624
33. Nokelainen M., Helaakoski T., Myllyharju J., Notbohm H., Pihlajaniemi T., Fietzek P.P., and Kivirikko K.I. Recombinant human type II collagens with low and high levels of hydroxylysine and its glycosylated forms show marked differences in fibrillogenesis in vitro. J. Biol. Chem. 274 (1999) 8988-8992
34. Paimela L., Laasonen L., Helve T., et al. Comparison of the original and the modified Larsen methods and the Sharp method in scoring radiographic progression in early rheumatoid arthritis. J. Rheumatol. 25 (1998) 1063-1066
35. Rosoniec E., Cremer M., Kang A., and Myers L. Collagen-induced arthristis. In: Coligan J., Kruisbeek A., Margulies D., Shevach E., and Strober W. (Eds). Current Protocols in Immunology (1996), New York 15.5.1
36. Ruderman E.M. Current and future pharmaceutical therapy for rheumatoid arthritis. Curr. Pharm. Des. 11 (2005) 671-684
37. Sandell L.J., Prentice H.L., Kravis D., and Upholt W.B. Structure and sequence of the chicken type II procollagen gene. Characterization of the region encoding the carboxyl-terminal telopeptide and propeptide. J. Biol. Chem. 259 (1984) 7826-7834
38. Sieper J., Kary S., Sorensen H., Alten R., Eggens U., Huge W., Hiepe F., Kuhne A., Listing J., Ulbrich N., Braun J., Zink A., and Mitchison N.A. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 39 (1996) 41-51
39. Steinmam L. Immune therapy fpr autoimmune diseases. Science 305 (2004) 212-216
40. Tang B., Chiang T.M., Brand D.D., Gumanovskaya M.L., Stuart J.M., Kang A.H., and Myers L.K. Molecular definition and characterization of recombinant bovine CB8 and CB10: immunogenicity and arthritogenicity. Clin. Immunol. 92 (1999) 256-264
41. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K.L., Hafler D.A., and Weiner H.L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 (1993) 1727-1730
42. Vuorela A., Myllyharju J., Nissi R., Pihlajaniemi T., and Kivirikko K.I. Assembly of human prolyl 4-hydroxylase and type III collagen in the yeast pichia pastoris: formation of a stable enzyme tetramer requires coexpression with collagen and assembly of a stable collagen requires coexpression with prolyl 4-hydroxylase. EMBO J. 16 (1997) 6702-6712
43. Wang H., Shen Y.X., Wei W., Zhou A.W., Zhang L.L., Yue L., and Xu S.Y. Effect of chicken collagen type II on collagen 2induced arthritis in mice. Chin. Pharmacol. Bull. 18 (2002) 76-79
44. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., Jackson C.G., Lange M., and Burge D.J. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340 (1999) 253-259
45. Williams R.O. Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol. Med. 98 (2004) 207-216
46. Wu H.Y., and Weiner H.L. Oral tolerance. Immunol. Res. 28 (2003) 265-284
47. Xi C., Liu N., Liang F., Guo S., Sun Y., Yang F., and Xi Y. Molecular cloning, characterization and localization of chicken type II procollagen gene. Gene 366 (2006) 67-76
48. Xu H., and Xi Y.Z. Perspectives in gene therapy for autoimmune diseases. Nat. Med. J. China 86 (2006) 933-935
49. Yan J.X., Wait R., Berkelman T., Harry R.A., Westbrook J.A., Wheeler C.H., and Dunn M.J. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21 (2000) 3666-3672
50. Zhang L.L., Wei W., Yan S.X., Sun W.Y., Yue L., Wan H., Wu C.Y., Wang N.P., and Li C.Y. Prophylactic effects of glucosides of cheanomeles speciosa on collagen2induced arthritis in mice. Chin. Pharmacol. Bull. 20 (2004) 95-100